Johnson & Johnson (JNJ) has recalled more than 53,000 Duragesic pain-relief skin patches because at least one patch in the lot was found to have small crystals of the potent active ingredient. J&J voluntarily recalled one lot of Duragesic CII patches from wholesalers in April, said J&J spokesman William Foster. He said the affected lot was safe and effective, and J&J hasn’t received any reports of adverse health events associated with the product quality of the lot. A notice of the Duragesic recall was posted on the Food and Drug Administration’s website in June. It was classified as a “Class III” recall, which means the problem isn’t likely to cause adverse health consequences.
